FTC Orders Hikma To Shed Drugs For $112M Baxter Deal

The Federal Trade Commission on Wednesday ordered Hikma Pharmaceuticals PLC to sell off an anti-seizure drug and an allergy and nausea treatment in order to go through with its $111.5 million...

Already a subscriber? Click here to view full article